Medindia

X

Use of TIGRŽ Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons

Monday, May 23, 2011 General News J E 4
Advertisement

SINGAPORE, May 23, 2011 /PRNewswire/ -- Singapore company Novus Scientific Pte. Ltd announced that the TRAM Flap study (Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGRŽ (100% Resorbable) vs Polypropylene (Permanent) Mesh) has passed the 20 patient mark, representing approximately one quarter of the 86 patient study compliment.

This groundbreaking multi-center, randomized trial involves University of California San Diego (UCSD) in the U.S. as well as National University Hospital and Tan Tock Seng Hospital in Singapore. Surgeons from all three study sites will be in attendance at IPRAS 2011, Vancouver, Canada, May 22nd-27th, 2011. Novus Scientific will also be present at IPRAS as an exhibitor at booth 808.

"We are very optimistic about the early results using TIGRŽ Matrix in this TRAM Flap study.  TIGRŽ Matrix may provide a good option to avoid long-term complications associated with permanent meshes and the high cost of using biological meshes."- James J. Chao, MD FACS, Study Investigator, Professor of Plastic Surgery and Orthopedic Surgery, University of California, San Diego (UCSD) Medical Centre, USA.

"We are proud to have reached this important milestone of the study and it was truly a great team effort by all study investigators in the 3 hospitals. Early results for TIGRŽ Matrix look excellent."- Associate Professor Thiam Chye Lim, Principal Investigator & Head of Division of Plastic, Reconstructive and Aesthetic Surgery, National University Hospital, Singapore.

"We're very pleased to be part of this important study and with how TIGRŽ Matrix feels and conforms to the donor site. So far, results are good and look very promising."- Dr. Marcus Wong, Study Investigator, Consultant and Section Head, Plastic, Reconstructive and Aesthetic Surgery, Tan Tock Seng Hospital, Singapore.

TIGRŽ Matrix is the World's 1st Long-Term Resorbable Synthetic Mesh. US FDA cleared TIGRŽ Matrix Surgical Mesh for use in reinforcement of soft tissues where weakness exists in February 2010.

About Novus Scientific

Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices. Global HQ is in Singapore while European Headquarters and the core R&D function are in Uppsala, Sweden. The company's roots are Swedish as all the founders of Novus Scientific are previous owners / senior managers / members of the soft tissue-engineering project within Uppsala-based, Radi Medical Systems AB (now owned by St. Jude Medical Inc). The US Division, Novus Scientific, Inc. is headquartered near Boston, one of the world's foremost medical research cities. From this hub, Novus Scientific, Inc. will distribute TIGRŽ Matrix Surgical Mesh throughout the United States, Canada, and Latin America.

TIGRŽ is a trademark of Novus Scientific Pte. Ltd

CONTACT:  

Mark Hawthorne: +44 7748 988705 - mark.hawthorne@novusscientific.comJames Archetto: +1-781-577-2599 - jim.archetto@novusscientific.com, both of Novus Scientific www.novusscientific.com

SOURCE Novus Scientific Pte. Ltd

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Data Shows Massive Disparity in Professor Producti...
S
Amscot Financial Contributes Mini-Grants to 25 Non...